Zacks Investment Research on MSN19h
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung CancerJ&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...
LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding ...
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback